Tags

Type your tag names separated by a space and hit enter

A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.
Fertil Steril. 2006 Feb; 85(2):428-35.FS

Abstract

OBJECTIVE

To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS).

DESIGN

Randomized controlled trial (RCT).

SETTING

A university teaching hospital in Jeddah, Saudi Arabia.

PATIENT(S)

Twenty-five women with CC-resistant PCOS.

INTERVENTION(S)

Twelve women were assigned to the rosiglitazone and CC group, and 13 women were assigned to the metformin and CC group for three treatment cycles. The first cycle was started on the first day of the period with either rosiglitazone (4 mg twice daily) or metformin (500 mg three times daily) and continued for three cycles. Clomiphene citrate (100 mg) from the third day for 5 days was added to each cycle.

MAIN OUTCOME MEASURE(S)

Ovulation rate, number of follicles and estradiol (E2) on day 12 of the cycle, pregnancy rate, and changes in fasting glucose, serum insulin, HbA(1C), total testosterone (T), free T, luteinizing hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone sulfate (DHEAS), delta4-androstenedione (delta4-A), sex hormone-binding globulin (SHBG), insulin-like growth factor (IGF)-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3.

RESULT(S)

No significant differences were found in the baseline characteristics of both groups. Ovulation rate was significantly higher in the rosiglitazone and CC group (18 out of 28 cycles [[64.3%]]) than the metformin and CC group (12 out of 33 cycles [[36.4%]]) (P=.035). Similarly, statistically significant differences were found in the number of follicles > or =14 mm in the rosiglitazone and CC group (2.2 +/- 1) compared with the metformin and CC group (1.1 +/- 0.9) (P=.02) and E2 on day 12 of the cycle in the rosiglitazone and CC group (1,991 +/- 1,389 pmol/L) compared with the metformin and CC group (548 +/- 327) (P<.001). The pregnancy rate was also higher in the rosiglitazone and CC group (6 out of 12 [[50%]] women) than the metformin and CC group (5 out of 13 [[38.5%]] women), but did not reach statistical significance (P=.58). Both groups showed no significant changes in fasting plasma glucose or HbA(1C) or IGFBP-3 values. However, in both groups, fasting serum insulin, total T, free T, LH, DHEA-S, delta4A, and IGF-1 levels decreased significantly, and SHBG and IGFBP-1 exhibited significant increases.

CONCLUSION(S)

These findings suggest that short-term use of rosiglitazone and CC is more efficacious than metformin and CC in ovulation induction in women with CC-resistant PCOS.

Authors+Show Affiliations

Rouzi AA
Department of Obstetrics and Gynecology, King Abdulaziz University, Jeddah, Saudi Arabia. aarouzi@hotmail.com
Ardawi MS
No affiliation info available

MeSH

AdultClomipheneDrug ResistanceDrug Therapy, CombinationFemaleFertility Agents, FemaleHormonesHumansMetforminOvarian FollicleOvulationOvulation InductionPolycystic Ovary SyndromePregnancyPregnancy RateRosiglitazoneThiazolidinedionesTreatment OutcomeUltrasonography

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16595222

Citation

Rouzi, Abdulrahim A., and Mohammed Salleh M. Ardawi. "A Randomized Controlled Trial of the Efficacy of Rosiglitazone and Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Women With Clomiphene Citrate-resistant Polycystic Ovary Syndrome." Fertility and Sterility, vol. 85, no. 2, 2006, pp. 428-35.
Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2006;85(2):428-35.
Rouzi, A. A., & Ardawi, M. S. (2006). A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertility and Sterility, 85(2), 428-35.
Rouzi AA, Ardawi MS. A Randomized Controlled Trial of the Efficacy of Rosiglitazone and Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Women With Clomiphene Citrate-resistant Polycystic Ovary Syndrome. Fertil Steril. 2006;85(2):428-35. PubMed PMID: 16595222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. AU - Rouzi,Abdulrahim A, AU - Ardawi,Mohammed Salleh M, PY - 2005/01/08/received PY - 2005/07/05/revised PY - 2005/07/05/accepted PY - 2006/4/6/pubmed PY - 2006/5/9/medline PY - 2006/4/6/entrez SP - 428 EP - 35 JF - Fertility and sterility JO - Fertil Steril VL - 85 IS - 2 N2 - OBJECTIVE: To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS). DESIGN: Randomized controlled trial (RCT). SETTING: A university teaching hospital in Jeddah, Saudi Arabia. PATIENT(S): Twenty-five women with CC-resistant PCOS. INTERVENTION(S): Twelve women were assigned to the rosiglitazone and CC group, and 13 women were assigned to the metformin and CC group for three treatment cycles. The first cycle was started on the first day of the period with either rosiglitazone (4 mg twice daily) or metformin (500 mg three times daily) and continued for three cycles. Clomiphene citrate (100 mg) from the third day for 5 days was added to each cycle. MAIN OUTCOME MEASURE(S): Ovulation rate, number of follicles and estradiol (E2) on day 12 of the cycle, pregnancy rate, and changes in fasting glucose, serum insulin, HbA(1C), total testosterone (T), free T, luteinizing hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone sulfate (DHEAS), delta4-androstenedione (delta4-A), sex hormone-binding globulin (SHBG), insulin-like growth factor (IGF)-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3. RESULT(S): No significant differences were found in the baseline characteristics of both groups. Ovulation rate was significantly higher in the rosiglitazone and CC group (18 out of 28 cycles [[64.3%]]) than the metformin and CC group (12 out of 33 cycles [[36.4%]]) (P=.035). Similarly, statistically significant differences were found in the number of follicles > or =14 mm in the rosiglitazone and CC group (2.2 +/- 1) compared with the metformin and CC group (1.1 +/- 0.9) (P=.02) and E2 on day 12 of the cycle in the rosiglitazone and CC group (1,991 +/- 1,389 pmol/L) compared with the metformin and CC group (548 +/- 327) (P<.001). The pregnancy rate was also higher in the rosiglitazone and CC group (6 out of 12 [[50%]] women) than the metformin and CC group (5 out of 13 [[38.5%]] women), but did not reach statistical significance (P=.58). Both groups showed no significant changes in fasting plasma glucose or HbA(1C) or IGFBP-3 values. However, in both groups, fasting serum insulin, total T, free T, LH, DHEA-S, delta4A, and IGF-1 levels decreased significantly, and SHBG and IGFBP-1 exhibited significant increases. CONCLUSION(S): These findings suggest that short-term use of rosiglitazone and CC is more efficacious than metformin and CC in ovulation induction in women with CC-resistant PCOS. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/16595222/A_randomized_controlled_trial_of_the_efficacy_of_rosiglitazone_and_clomiphene_citrate_versus_metformin_and_clomiphene_citrate_in_women_with_clomiphene_citrate_resistant_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓15]

Related Citations

More